Corrigendum to 'Health-related quality of life in patients with advanced well-differentiated pancreatic and extrapancreatic neuroendocrine tumors treated with surufatinib versus placebo: Results from two randomized, double-blind, phase III trials (SANET-p and SANET-ep)' [European Journal of Cancer 169 (2022) 1–9]. (January 2023) - Li, Jiarui; Cheng, Yuejuan; Bai, Chunmei; Xu, Jianming; Shen, Lin; Li, Jie; Zhou, Zhiwei; Li, Zhiping; Chi, Yihebali; Yu, Xianjun; Li, Enxiao; Xu, Nong; et al.